-$0.59 Earnings Per Share Expected for Catalyst Biosciences Inc (CBIO) This Quarter

Brokerages expect Catalyst Biosciences Inc (NASDAQ:CBIO) to report earnings per share of ($0.59) for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Catalyst Biosciences’ earnings. Catalyst Biosciences reported earnings per share of ($0.96) during the same quarter last year, which indicates a positive year-over-year growth rate of 38.5%. The company is expected to issue its next earnings results on Thursday, March 7th.

According to Zacks, analysts expect that Catalyst Biosciences will report full year earnings of ($2.27) per share for the current fiscal year. For the next financial year, analysts forecast that the business will post earnings of ($2.86) per share. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that follow Catalyst Biosciences.

Catalyst Biosciences (NASDAQ:CBIO) last released its quarterly earnings data on Friday, November 2nd. The biopharmaceutical company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.05). Catalyst Biosciences had a negative net margin of 2,983.40% and a negative return on equity of 22.67%.

Separately, Zacks Investment Research cut shares of Catalyst Biosciences from a “buy” rating to a “hold” rating in a report on Wednesday, August 8th. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $19.83.

A number of hedge funds have recently made changes to their positions in the business. AQR Capital Management LLC increased its holdings in Catalyst Biosciences by 303.3% during the third quarter. AQR Capital Management LLC now owns 93,769 shares of the biopharmaceutical company’s stock valued at $1,011,000 after buying an additional 70,519 shares during the last quarter. Nexthera Capital LP increased its holdings in Catalyst Biosciences by 13.4% during the third quarter. Nexthera Capital LP now owns 892,579 shares of the biopharmaceutical company’s stock valued at $9,622,000 after buying an additional 105,714 shares during the last quarter. Sio Capital Management LLC increased its holdings in Catalyst Biosciences by 16.9% during the third quarter. Sio Capital Management LLC now owns 550,977 shares of the biopharmaceutical company’s stock valued at $5,940,000 after buying an additional 79,529 shares during the last quarter. Prosight Management LP purchased a new stake in Catalyst Biosciences during the third quarter valued at approximately $2,550,000. Finally, JBF Capital Inc. purchased a new stake in Catalyst Biosciences during the third quarter valued at approximately $323,000. 67.14% of the stock is owned by institutional investors and hedge funds.

Shares of CBIO traded up $0.13 during mid-day trading on Monday, hitting $10.68. 154,957 shares of the company traded hands, compared to its average volume of 179,426. Catalyst Biosciences has a 1 year low of $6.26 and a 1 year high of $37.00. The stock has a market capitalization of $126.00 million, a price-to-earnings ratio of -1.43 and a beta of 2.36.

Catalyst Biosciences Company Profile

Catalyst Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on developing medicines to address hematology indications. Its product pipeline includes marzeptacog alfa, a Factor VIIa variant that is in a Phase II/III clinical trial for the prophylactic treatment of individuals with severe hemophilia A and B with inhibitors.

See Also: How to Track your Portfolio in Google Finance

Get a free copy of the Zacks research report on Catalyst Biosciences (CBIO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Catalyst Biosciences (NASDAQ:CBIO)

Receive News & Ratings for Catalyst Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit